Virological failure rates and HIV‐1 drug resistance patterns in patients on first‐line antiretroviral treatment in semirural and rural Gabon

• Published in: Journal of the International AIDS Society Vol. 15; no. 2; pp. 17985 - n/a
• Main Authors: Liégeois, Florian, Vella, Caroline, Eymard‐Duvernay, Sabrina, Sica, Jeanne, Makosso, Laurent, Mouinga‐Ondémé, Augustin, Mongo, Arnaud Delis, Boué, Vanina, Butel, Christelle, Peeters, Martine, Gonzalez, Jean‐Paul, Delaporte, Eric, Rouet, François
• Format: Journal Article
• Language: English
• Published: Switzerland International AIDS Society 01.04.2012; John Wiley & Sons, Inc
• Subjects: Acquired immune deficiency syndrome; Adult; Africa; AIDS; AIDS/HIV; Anti-HIV agents; Anti-HIV Agents - pharmacology; Anti-HIV Agents - therapeutic use; Antiretroviral agents; Antiretroviral drugs; antiretroviral therapy; Antiviral agents; Cross-Sectional Studies; DNA polymerases; Dosage and administration; Drug resistance; Drug Resistance, Viral; Drug therapy; Failure; Female; Gabon - epidemiology; Genetic diversity; Highly active antiretroviral therapy; HIV; HIV (Viruses); HIV infection; HIV Infections - epidemiology; HIV Infections - virology; HIV-1 - drug effects; HIV-1 - genetics; Human immunodeficiency virus; Humans; Laboratories; Male; Middle Aged; Mortality; Mutation; Patient outcomes; Plasma; Public health; resistance; Risk Factors; RNA; Rural Population; Short Report; Statistical analysis; Studies; Systematic review; Toy industry; viral load; Gabon; Africa; South Africa; Cameroon
• ISSN: 1758-2652; 1758-2652
• DOI: 10.7448/IAS.15.2.17985

Introduction As antiretroviral treatment (ART) continues to expand in resource‐limited countries, the emergence of HIV drug resistance mutations (DRMs) is challenging in these settings. In Gabon (central Africa), no study has yet reported the virological effectiveness of initial ART given through routine HIV care. Methods Following the World Health Organization (WHO) recommendations, a cross‐sectional study with a one‐time HIV‐1 RNA viral load (VL) measurement was conducted in Gabon to assess virological failure (VF) defined by a VL result ≥1000 copies/ml and DRMs among adult patients living with non‐B HIV‐1 strains and receiving first‐line non‐nucleoside reverse transcriptase inhibitor (NNRTI)‐based antiretroviral therapy for at least 12 months. Risk factors associated with VF and DRMs were assessed. Results Between March 2010 and March 2011, a total of 375 patients were consecutively enrolled from two decentralized (one semirural and one rural) HIV care centres. Median time on ART was 33.6 months (range, 12–107). Overall, the rate of VF was 41.3% (36.4–46.4). Among viremic patients, 56.7% (80/141) had at least one DRM and 37.6% had dual‐class resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and NNRTIs. The most frequent DRMs were K103N/S (46.1%) and M184V/I (37.6%). Thymidine analogue mutations were found in 10.6%. Independent risk factors associated with VF were being followed up at the semirural centre (P=0.033), having experienced unstructured treatment interruptions (P=0.0044), and having low CD4+ counts at enrolment (P<0.0001). A longer time on ART (P=0.0008) and being followed up at the rural centre (P=0.021) were risk factors for DRMs. Conclusions This is the first study conducted in Gabon providing VF rates and DRM patterns in adult patients receiving first‐line ART. In sub‐Saharan Africa, where NNRTI‐based regimens are recommended as the standard for first‐line ART, strengthening virological monitoring together with preventing unplanned treatment interruptions are a global public health priority.